The news of Oppenheimer assuming Nurix Therapeutics with an Outperform rating and setting a price target of $25 is likely to have a positive impact on the stock price in the short term. This is because the Outperform rating indicates that the analyst believes the stock will outperform its peers, and the price target of $25 suggests potential upside from the current price.